What Is the Current State of Research in Promoter Hypermethylation and Cancer?
Research in this area is rapidly evolving. Advances in epigenomic technologies, such as next-generation sequencing and bisulfite sequencing, have enhanced our understanding of methylation patterns in cancer. Ongoing clinical trials are evaluating the efficacy of DNMT inhibitors and exploring combination therapies with other anticancer agents to overcome resistance and improve outcomes.
